This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Novo Nordisk CagriSema Trial Lawsuit
Business class action

Novo Nordisk CagriSema Trial Lawsuit

Analysis based on 42 articles · First reported Feb 02, 2025 · Last updated Mar 24, 2025

Sentiment
-50
Attention
4
Articles
42
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Novo Nordisk, initiated by firms like Levi & Korsinsky, Rosen Law Firm, and The Gross Law Firm, has negatively impacted Novo Nordisk's stock price due to allegations of misleading investors about its REDEFINE-1 trial results. This event highlights the importance of transparent communication from pharmaceutical companies regarding clinical trial outcomes, as failures can lead to significant financial repercussions and legal challenges.

Pharmaceuticals Legal Services
Event Summary

Novo Nordisk is facing a class action securities lawsuit filed by law firms including Levi & Korsinsky, Rosen Law Firm, and The Gross Law Firm. The lawsuit alleges that Novo Nordisk made misleading statements to investors between November 2, 2022, and December 19, 2024, regarding its phase 3 CagriSema study on obesity, named 'REDEFINE-1'. Specifically, the complaint states that Novo Nordisk provided overwhelmingly positive statements about the trial, including an expected minimum of 25% average weight loss, while failing to disclose that the trial protocol allowed patients to modify their dosage. On December 20, 2024, Novo Nordisk announced that the trial showed only 22.7% weight loss after 68 weeks, falling short of expectations, and that only 57.3% of patients were on the highest dosage. Following this announcement, Novo Nordisk's stock price dropped by $18.44 per share to $85.00. Investors who suffered losses during this period have until March 25, 2025, to request to be appointed as lead plaintiff in the lawsuit.

Key Actions
100 Levi & Korsinsky notifies investors Novo Nordisk
90 Novo Nordisk issued press release
70 Rosen Law Firm filed class action Novo Nordisk
Entities Involved
stock
Novo Nordisk
Novo Nordisk is facing a class action lawsuit for allegedly misleading investors about the results of its REDEFINE-1 trial for CagriSema, leading to a significant drop in its stock price.
Importance 100.0 Sentiment -70.0
priv
Levi & Korsinsky
Levi & Korsinsky is a law firm actively notifying investors and encouraging them to join the class action lawsuit against Novo Nordisk.
Importance 80.0 Sentiment 50.0
per
Joseph E. Levi
Joseph E. Levi is an attorney at Levi & Korsinsky, serving as a contact for investors interested in the class action lawsuit against Novo Nordisk.
Importance 40.0 Sentiment 30.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
Relationships
Levi & Korsinsky related ↔ Joseph E. Levi
Levi & Korsinsky related ↔ Rosen Law Firm
Levi & Korsinsky related ↔ Philip Kim
Levi & Korsinsky related ↔ Lawrence Rosen
Joseph E. Levi related ↔ Rosen Law Firm
Joseph E. Levi related ↔ Philip Kim
Joseph E. Levi related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Philip Kim attorney ↔ Lawrence Rosen Philip Kim is an attorney at the Rosen Law Firm, working under the direction of founding partner Lawrence Rosen. Kim fre
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.